Piotr Eder

List of Publications by Year in descending order

90 papers	2,147 citations	516215 16 h-index	276539 41 g-index
94 all docs	94 docs citations	94 times ranked	2254 citing authors

#	Article	IF	Citations
1	Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series. Journal of Crohn's and Colitis, 2022, 16, 91-97.	0.6	6
2	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. Journal of Crohn's and Colitis, 2022, 16, 179-189.	0.6	120
3	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn's and Colitis, 2022, 16, 2-17.	0.6	288
4	Hydrogels for Modified-release Drug Delivery Systems. Current Pharmaceutical Design, 2022, 28, 609-618.	0.9	14
5	Obesity and the Brain. International Journal of Molecular Sciences, 2022, 23, 6145.	1.8	8
6	Self-Medication with Drotaverine among Patients with Common Abdominal Symptoms and Treatment Efficacy from the Perspectives of Patients and General Practitionersâ€"An Observational, Retrospective, Cross-Sectional Study Using Real-World Data. Journal of Clinical Medicine, 2022, 11, 3156.	1.0	0
7	Artificial Gastrointestinal Models for Nutraceuticals Researchâ€"Achievements and Challenges: A Practical Review. Nutrients, 2022, 14, 2560.	1.7	8
8	Vitamin D, Vitamin D Receptor (VDR) Gene Polymorphisms (ApaI and FokI), and Bone Mineral Density in Patients With Inflammatory Bowel Disease. Journal of Clinical Densitometry, 2021, 24, 233-242.	0.5	5
9	Is there a relation between vitamin D, interleukin-17, and bone mineral density in patients with inflammatory bowel disease?. Archives of Medical Science, 2021, 17, 662-674.	0.4	4
10	Position statement of the Polish Society of Gastroenterology and the National Gastroenterology Consultant on vaccination against COVID-19 among patients with inflammatory bowel diseases. Przeglad Gastroenterologiczny, 2021, 16, 2-4.	0.3	7
11	A Vicious Cycle of Osteosarcopenia in Inflammatory Bowel Diseasesâ€"Aetiology, Clinical Implications and Therapeutic Perspectives. Nutrients, 2021, 13, 293.	1.7	8
12	Dysbiosis of gut microbiota in Polish patients with ulcerative colitis: a pilot study. Scientific Reports, 2021, 11, 2166.	1.6	47
13	Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110364.	1.4	5
14	Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Polish Archives of Internal Medicine, 2021, 131, 226-232.	0.3	6
15	Multidimensional Disadvantages of a Gluten-Free Diet in Celiac Disease: A Narrative Review. Nutrients, 2021, 13, 643.	1.7	11
16	Black esophagus: an unusual etiology of the upper gastrointestinal bleeding. Polish Archives of Internal Medicine, 2021, 131, 377-378.	0.3	0
17	Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease. Frontiers in Immunology, 2021, 12, 615539.	2.2	11
18	Cancer Nanopharmaceuticals: Physicochemical Characterization and In Vitro/In Vivo Applications. Cancers, 2021, 13, 1896.	1.7	15

#	Article	IF	Citations
19	Associations of Lifestyle Factors with Osteopenia and Osteoporosis in Polish Patients with Inflammatory Bowel Disease. Nutrients, 2021, 13, 1863.	1.7	14
20	What Links an Increased Cardiovascular Risk and Inflammatory Bowel Disease? A Narrative Review. Nutrients, 2021, 13, 2661.	1.7	14
21	Social Distancing during COVID-19 Pandemic among Inflammatory Bowel Disease Patients. Journal of Clinical Medicine, 2021, 10, 3689.	1.0	3
22	Potential Salivary Markers for Differential Diagnosis of Crohnâ€™s Disease and Ulcerative Colitis. Life, 2021, 11, 943.	1.1	12
23	Myostatin and Follistatinâ€”New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications. Biomedicines, 2021, 9, 1301.	1.4	7
24	Immunogenetic, Molecular and Microbiotic Determinants of Eosinophilic Esophagitis and Clinical Practiceâ€”A New Perspective of an Old Disease. International Journal of Molecular Sciences, 2021, 22, 10830.	1.8	6
25	How could nanobiotechnology improve treatment outcomes of anti-TNF-Î± therapy in inflammatory bowel disease? Current knowledge, future directions. Journal of Nanobiotechnology, 2021, 19, 346.	4.2	10
26	Guidelines for the management of patients with Crohnâ€™s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Przeglad Gastroenterologiczny, 2021, 16, 257-296.	0.3	10
27	Iron Deficiency Anemia in Inflammatory Bowel Diseasesâ€”A Narrative Review. Nutrients, 2021, 13, 4008.	1.7	25
28	Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease. Life, 2021, 11, 1409.	1.1	10
29	Metabolic link between obesity and autoimmune diseases. European Cytokine Network, 2021, 32, 64-72.	1.1	1
30	Historical Upheavals and Eponyms in Crohnâ€™s Diseaseâ€”Is There Any Relation?. Journal of Crohn's and Colitis, 2020, 14, 719-719.	0.6	0
31	Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults. International Journal of Molecular Sciences, 2020, 21, 5223.	1.8	10
32	Is the Retinol-Binding Protein 4 a Possible Risk Factor for Cardiovascular Diseases in Obesity?. International Journal of Molecular Sciences, 2020, 21, 5229.	1.8	25
33	Is Polymorphism in the Apoptosis and Inflammatory Pathway Genes Associated With a Primary Response to Anti-TNF Therapy in Crohnâ€™s Disease Patients?. Frontiers in Pharmacology, 2020, 11, 1207.	1.6	7
34	The position statement of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic. Przeglad Gastroenterologiczny, 2020, 15, 85-88.	0.3	5
35	Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules, 2020, 25, 3731.	1.7	640
36	Two- and Three-Dimensional Spectrofluorimetric Qualitative Analysis of Selected Vegetable Oils for Biomedical Applications. Molecules, 2020, 25, 5608.	1.7	1

#	Article	IF	Citations
37	Diet and Nutritional Factors in Male (In)fertilityâ€"Underestimated Factors. Journal of Clinical Medicine, 2020, 9, 1400.	1.0	79
38	Milk and dairy product consumption in patients with inflammatory bowel disease: Helpful or harmful to bone mineral density?. Nutrition, 2020, 79-80, 110830.	1.1	8
39	Properties, Extraction Methods, and Delivery Systems for Curcumin as a Natural Source of Beneficial Health Effects. Medicina (Lithuania), 2020, 56, 336.	0.8	55
40	Nanotoxicology and Nanosafety: Safety-by-Design and Testing at a Glance. International Journal of Environmental Research and Public Health, 2020, 17, 4657.	1.2	114
41	The introduction of the IBD Disk in Poland â€“ a new tool for assessing disability in patients with inflammatory bowel disease. Przeglad Gastroenterologiczny, 2020, 15, 55-59.	0.3	4
42	Addressing multiple gastroenterological aspects of COVID-19. Polish Archives of Internal Medicine, 2020, 130, 420-430.	0.3	8
43	The Role of Adipose Tissue in the Pathogenesis and Therapeutic Outcomes of Inflammatory Bowel Disease. Cells, 2019, 8, 628.	1.8	51
44	ESR1 Gene Variants Are Predictive of Osteoporosis in Female Patients with Crohnâ€™s Disease. Journal of Clinical Medicine, 2019, 8, 1306.	1.0	15
45	Dietary Support in Elderly Patients with Inflammatory Bowel Disease. Nutrients, 2019, 11, 1421.	1.7	9
46	Treatment of Crohnâ€™s anal fistulas guided by magnetic resonance imaging. Przeglad Gastroenterologiczny, 2019, 14, 55-61.	0.3	4
47	Biosimilar biological drugs in the treatment of inflammatory bowel diseases. Przeglad Gastroenterologiczny, 2019, 14, 223-227.	0.3	1
48	Does Only Sex Matter? Complexity of the Association Between Vdr Gene BsmI Single Nucleotide Polymorphism and Immune Response in IBD. Inflammatory Bowel Diseases, 2019, 25, e56-e57.	0.9	1
49	Vitamin D receptor (VDR) TaqI polymorphism, vitamin D and bone mineral density in patients with inflammatory bowel diseases. Advances in Clinical and Experimental Medicine, 2019, 28, 955-960.	0.6	6
50	Position of the expert group on the current practice and prospects for the treatment of complex perirectal fistulas in the course of Crohn's disease. Polski Przeglad Chirurgiczny, 2019, 91, 1-9.	0.2	7
51	Long-term prognostic utility of selected acute phase proteins in colorectal cancer. Polish Archives of Internal Medicine, 2019, 129, 292-294.	0.3	1
52	Hereditary Angioedema: An Overlooked Cause of Recurrent Abdominal Pain and Free Peritoneal Fluid. Clinical Gastroenterology and Hepatology, 2018, 16, e43-e44.	2.4	2
53	Interleukin 6, osteoprotegerin, sRANKL and bone metabolism in inflammatory bowel diseases. Advances in Clinical and Experimental Medicine, 2018, 27, 449-453.	0.6	13
54	Prevalence of osteoporosis and osteopenia in a population of patients with inflammatory bowel diseases from the Wielkopolska Region. Polish Archives of Internal Medicine, 2018, 128, 447-454.	0.3	17

#	Article	IF	Citations
55	The c.29T>C polymorphism of the transforming growth factor beta-1 (TGFB1) gene, bone mineral density and the occurrence of low-energy fractures in patients with inflammatory bowel disease. Molecular Biology Reports, 2017, 44, 455-461.	1.0	10
56	Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-Î± antibodies. World Journal of Gastroenterology, 2017, 23, 135.	1.4	8
57	Possible under-treatment of women in Poland with Crohnâ€™s disease: a subgroup analysis from a prospective multicenter study of the use of anti-TNFs. Polish Archives of Internal Medicine, 2017, 127, 674-680.	0.3	3
58	Osteoprotegerin, s-RANKL, and selected interleukins in the pathology of bone metabolism in patients with Crohnâ€™s disease. Przeglad Gastroenterologiczny, 2016, 1, 30-34.	0.3	7
59	Intestinal healing after anti-TNF induction therapy predicts long-term response to one-year treatment in patients with ileocolonic Crohnâ€™s disease naive to anti-TNF agents. Przeglad Gastroenterologiczny, 2016, 3, 187-193.	0.3	14
60	Diagnostic importance of faecal markers in long-term monitoring of anti-TNF-ï¡ therapy in primary responders with Crohnâ€™s disease. Przeglad Gastroenterologiczny, 2016, 4, 232-238.	0.3	2
61	An increase in serum tumour necrosis factor-Î± during anti-tumour necrosis factor-Î± therapy for Crohn's disease â€“ A paradox or a predictive index?. Digestive and Liver Disease, 2016, 48, 1168-1171.	0.4	8
62	Bone Metabolism and the c.-223CÂ>ÂT Polymorphism in the 5â€²UTR Region of the Osteoprotegerin Gene in Patients with Inflammatory Bowel Disease. Calcified Tissue International, 2016, 99, 616-624.	1.5	20
63	Palliative treatment of anal fistulas in <scp>C</scp>rohn's disease. ANZ Journal of Surgery, 2016, 86, 148-151.	0.3	1
64	Osteoporosis in Gastrointestinal Diseases. Advances in Clinical and Experimental Medicine, 2016, 25, 185-190.	0.6	26
65	Update on the mechanisms of action of antiâ€TNF-Î± antibodies and their clinical implications in inflammatory bowel disease. Polish Archives of Internal Medicine, 2016, 126, 772-780.	0.3	9
66	The influence of anti-TNF therapy on CD31 and VEGF expression in colonic mucosa of Crohnâ€™s disease patients in relation to mucosal healing. Folia Histochemica Et Cytobiologica, 2016, 54, 75-80.	0.6	12
67	Evaluation of antimicrobial resistance of Helicobacter pylori in the last 15 years in West Poland. Acta Microbiologica Et Immunologica Hungarica, 2015, 62, 287-293.	0.4	13
68	Disturbances in apoptosis of lamina propria lymphocytes in Crohnâ€™s disease. Archives of Medical Science, 2015, 6, 1279-1285.	0.4	9
69	Is faecal calprotectin equally useful in all Crohnâ€™s disease locations? A prospective, comparative study. Archives of Medical Science, 2015, 2, 353-361.	0.4	42
70	Current management of anal fistulas in Crohnâ€™s disease. Przeglad Gastroenterologiczny, 2015, 2, 83-88.	0.3	12
71	New pharmaceuticals in inflammatory bowel disease. Przeglad Gastroenterologiczny, 2015, 2, 57-60.	0.3	5
72	Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohnâ€™s disease treated with anti-tumor necrosis factor antibodies. Scientific Reports, 2015, 5, 10223.	1.6	16

#	Article	IF	Citations
73	The influence of anti-TNF therapy on the magnetic resonance enterographic parameters of Crohnâ€™s disease activity. Abdominal Imaging, 2015, 40, 2210-2218.	2.0	23
74	Agomelatine-induced liver injury in a patient with choledocholithiasis. Acta Neuropsychiatrica, 2015, 27, 56-59.	1.0	4
75	The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity. European Journal of Internal Medicine, 2015, 26, 623-627.	1.0	10
76	Association of serum VEGF with clinical response to anti-TNFÎ± therapy for Crohnâ€™s disease. Cytokine, 2015, 76, 288-293.	1.4	8
77	Calcium and phosphate metabolism in patients with inflammatory bowel diseases. Polish Archives of Internal Medicine, 2015, 125, 588-590.	0.3	9
78	Angiogenesis-Related Proteins - Their Role in the Pathogenesis and Treatment of Inflammatory Bowel Disease. Current Protein and Peptide Science, 2015, 16, 249-258.	0.7	11
79	The importance of vitamin D in the pathology of bone metabolism in inflammatory bowel diseases. Archives of Medical Science, 2015, 11, 1028-32.	0.4	17
80	Calcium and phosphate metabolism in patients with inflammatory bowel diseases. , 2015, 125, 588-90.		4
81	Biosimilar medicines â€“ their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. Przeglad Gastroenterologiczny, 2014, 1, 1-3.	0.3	17
82	Alterations in programmed cell death mechanism and their role in the pathogenesis of inflammatory bowel diseases. Przeglad Gastroenterologiczny, 2014, 5, 275-279.	0.3	5
83	The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease â€” An immunohistochemical study. Journal of Crohn's and Colitis, 2013, 7, 706-716.	0.6	21
84	Guidelines for the management of ulcerative colitis. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology. Przeglad Gastroenterologiczny, 2013, 1, 1-20.	0.3	2
85	Simple Enterographic Activity Score for Crohnâ€™s Disease: comparison with endoscopic, biochemical, and clinical findings. Polish Archives of Internal Medicine, 2013, 123, 378-385.	0.3	10
86	Anti-TNF antibodies do not induce the apoptosis of lamina propria mononuclear cells in uninflamed intestinal tissue in patients with Crohnâ€™s disease. Folia Histochemica Et Cytobiologica, 2013, 51, 239-243.	0.6	2
87	Abdominal bloating â€“ an important symptom in everyday medical practice. Przeglad Gastroenterologiczny, 2012, 4, 197-202.	0.3	0
88	Guidelines for the management of Crohnâ€™s disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology. Przeglad Gastroenterologiczny, 2012, 6, 317-338.	0.3	10
89	Blockers of tumour necrosis factor-Î±: mechanisms of action. Przeglad Gastroenterologiczny, 2011, 5, 290-298.	0.3	2
90	Clinical utility of the assessment of fecal calprotectin in LeÅ›niowski-Crohn's disease. , 2008, 118, 622-6.		6